Abstract
To determine if higher bone mineral density (BMD) is a risk factor for breast cancer in women age 50 years and older. 37,860 women ≥50-year old with no previous breast cancer diagnosis had baseline BMD assessment between January 1999 and December 2007. Cox proportional hazards models were created for time to a new breast cancer as a function of lumbar spine or femoral neck BMD quartile (1st = lowest as reference) with adjustment for relevant covariates. A secondary analysis was performed to look for an association with estrogen receptor-positive (ER-positive) breast cancers. 794 invasive and in situ breast cancers (484 ER-positive) occurred with a median follow up of 5.4 years. Increased breast cancer risk was seen for the 3rd and 4th quartiles of lumbar spine BMD with hazard ratios (HRs) of 1.26 (95% CI, 1.01–1.58) and 1.45 (95% CI, 1.16–1.81), respectively and for the 3rd quartile of femoral neck BMD with a HR of 1.33 (95% CI, 1.07–1.64). A test for linear trend showed that lumbar spine BMD (P < 0.001) and femoral neck BMD (P = 0.04) were associated with increased risk. Higher lumbar spine BMD was also associated with increased risk of ER-positive breast cancer with HR of 1.45 (95% CI, 1.08–1.94), and 1.68 (95% CI, 1.24–2.27) for women in the 2nd and 4th quartiles, respectively. A test for linear trend showed lumbar spine BMD was associated with increasing risk of ER-positive breast cancer (P = 0.003). Increased ER-positive breast cancer risk was seen for the 3rd quartile of femoral neck BMD with a HR of 1.43 (95% CI, 1.08–1.89). Higher lumbar spine and femoral neck BMD are associated with higher risk of breast cancer in women ≥50-year old. Lumbar spine and femoral neck BMD are associated with increased risk of ER-positive breast cancer.
Similar content being viewed by others
References
Bray F, McCarron P, Parkin DM (2004) The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6(6):229–239
American Cancer Society: cancer facts and figures. http://www.cancer.org
Cummings SR, Duong T, Kenyon E et al (2002) Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287(2):216–220
Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333
Bernstein L (2002) Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia 7(1):3–15
Cauley JA, Gutai JP, Kuller LH et al (1988) Endogenous estrogen levels and calcium intake in postmenopausal women: relationships with cortical bone measures. JAMA 260(21):3150–3155
Felson DT, Zhang Y, Hannan MT et al (1993) The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 329(16):1141–1146
Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344(4):276–285
Santen RJ, Boyd NF, Chlebowski RT et al (2007) Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer 14(2):169–187
Tucker TC, Howe HL, Weir HK (1999) Certification for population-based cancer registries. J Regist Manag 26:24–27
Leslie WD, MacWilliam L, Lix L et al (2005) A population-based study of osteoporosis testing and treatment following introduction of a new bone densitometry service. Osteoporos Int 16(7):773–782
Leslie WD, Caetano PA, MacWilliam LR et al (2005) Construction and validation of a population-based bone densitometry database. J Clin Densitom 8:25–30
Leslie WD, Metge C (2003) Establishing a regional bone density program: lessons from the Manitoba experience. J Clin Densitom 6:275–282
Brown JP, Josse RG (2002) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167(10 suppl):S1–S34
Hansen KF, Binkley N, Christian R (2005) Interobserver reproducibility of criteria for vertebral body exclusion. J Bone Miner Res 20:501–508
Leslie WD (2006) The importance of spectrum bias on bone mineral density monitoring in clinical practice. Bone 39:361–368
van der Klift M, de Laet CE, Coebergh JW et al (2003) Bone mineral density and the risk of breast cancer; the Rotterdam study. Bone 32:211–216
Buist DS, Lacroix AZ, Barlow WE et al (2001) Bone mineral density and breast cancer risk in postmenopausal women. J Clin Epidemiol 54(4):417–422
Zhang Y, Kiel DP, Kreger BE et al (1997) Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 336(9):611–617
Lucas FL, Cauley JA, Stone RA (1998) Bone mineral density and risk of breast cancer: differences by family history of breast cancer. Study of Osteoporotic Fractures Research Group. Am J Epidemiol 148(1):22–29
Chen Z, Arendell L, Aickin M (2008) Hip bone density predicts breast cancer risk independently of Gail score. Results from the Women’s Health Initiative. Cancer 113(5):907–915
Cauley JA, Song J, Dowsett SA (2007) Risk factors for breast cancer in older women: the relative contribution of bone mineral density and other established risk factors. Breast Cancer Res Treat 102(2):181–188
Stewart A, Kumar V, Torgerson DJ et al (2005) Axial BMD, change in BMD and bone turnover do not predict breast cancer incidence in early postmenopausal women. Osteoporosis 16(12):1627–1632
Kerlikowske K, Shepherd J, Creasman J et al (2005) Are breast density and bone mineral density independent risk factors for breast cancer? J Natl Cancer Inst 97:368–374
Nelson RL, Turyk M, Kim J et al (2002) Bone mineral density and the subsequent risk of cancer in the NHANES I follow-up cohort. BMC Cancer 2(1):22
Tremollieres FA, Pouilles JM, Laparra J et al (2008) Bone mineral density at menopause does not predict breast cancer incidence. Osteoporos Int 19(10):1497–1504
Rosenberg LU, Einarsdottir K, Friman EI et al (2006) Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 15(12):2482–2488
Burshell AL, Song J, Dowsett SA et al (2008) Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis. Curr Med Res Opin 24(3):807–813
Chlebowski RT, Kuller LH, Prentice RL (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360:573–587
Pieta B, Samulak D, Opala T et al (2009) Women’s lifestyle and the risk of breast tumors. Eur J Gynaecol Oncol 30(2):186–189
Jacobi CE, de Bock GH, Siegerink B, et al. (2008) Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res Treat, May 30 (Epub ahead of print)
Acknowledgments
We are indebted to Katherine Fradette for her invaluable assistance and to Manitoba Health for providing data (HIPC No. 2007-8 56). This article has been reviewed and approved by the members of the Manitoba Bone Density Program Committee.
Disclaimers
The results and conclusions are those of the authors and no official endorsement by Manitoba Health is intended or should be inferred.
Funding
Supported by a research grant from the CancerCare Manitoba Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Grenier, D., Cooke, A.L., Lix, L. et al. Bone mineral density and risk of postmenopausal breast cancer. Breast Cancer Res Treat 126, 679–686 (2011). https://doi.org/10.1007/s10549-010-1138-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-010-1138-y